Overall, cemiplimab demonstrated a favorable benefit–risk profile in Japanese patients with squamous or non-squamous advanced NSCLC with no EGFR, ALK, or ROS1 aberrations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.